Septodont's Novocol Pharma division has secured $32.7 million Canadian ($26 million U.S.) from the Canadian government to further develop its injectable products.
The funding will increase biomanufacturing capability of fill-finish sterile injectables at Novocol Pharma's facility in Cambridge, Ontario, Septodont said.
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
